The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Interim results of an anti-SIRPα antibody, CC-95251, in R/R NHL
Amitkumar Mehta, MD, UAB School of Medicine, Birmingham, AL, discusses data from the dose-escalation, Phase I CC-95251-ST-001 trial (NCT03783403) of CC-95251, an anti-signal regulatory protein-alpha (SIRPα) antibody, in patients with CD20+ relapsed/refractory non-Hodgkin lymphoma (NHL). Patients predominantly with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) received 3, 10, or 20 mg/kg of CC-95251 with rituximab, and reported encouraging efficacy with an acceptable safety profile. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
